Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Bioelectronics Corp BIEL

BioElectronics Corporation is an electroceutical company. The Company develops wearables, neuromodulation devices to mitigate neurological diseases. Its pulsed shortwave therapy technology (PSWT) that uses low power pulsed electromagnetic fields regulate electrical activity of the nervous system. Its product line includes ActiPatch Musculoskeletal Pain Therapy, and RecoveryRx Post-operative and... see more

Recent & Breaking News (PINL:BIEL)

BioElectronics Corporation Announces the Publication of a Canine Arthritis Study

GlobeNewswire March 25, 2024

BioElectronics Corporation Announces the Publication of Pilot Study Results

GlobeNewswire February 23, 2024

BioElectronics Chairman Updates Investors

GlobeNewswire February 15, 2024

End of Year Message From the Chairman of the Board of BioElectronics

GlobeNewswire December 22, 2023

BioElectronics' Chairman Discusses Recent Clinical Research Findings

GlobeNewswire July 22, 2022

BioElectronics Corporation Enters Into a Distribution Agreement For RecoveryRx in Spain With PRIM Group

GlobeNewswire April 6, 2022

BioElectronics' RecoveryRx Pain Relief Device Receives Clearance from Cofepris, Launching Distribution in Mexico

GlobeNewswire March 30, 2022

BioElectronics Corporation Chairman Richard Staelin, Ph.D., Updates Company Achievements

GlobeNewswire February 28, 2022

BioElectronics Corporation Announces Major Lenders Forgoing Interest for a 3rd Consecutive Year; New Research Projects Underway

GlobeNewswire January 3, 2022

BioElectronics Corporation Reports Q3 Earnings

GlobeNewswire November 16, 2021

BioElectronics Corporation to Present at the NobleCon Online Pain Management Investor Forum on Channelchek.com

GlobeNewswire October 7, 2021

BioElectronics Corporation Discusses Q2 Financials

GlobeNewswire August 30, 2021

BioElectronics Corporation Reports Double Digit Quarterly Sales Growth, KT Health and DJO Launches Outpacing Forecasts

GlobeNewswire April 19, 2021

BioElectronics Corporation Announces Substantial Increase in 4th Quarter 2020 Revenue; Major Convertible Debt Holders Agree to Forego Interest in 2021

GlobeNewswire January 19, 2021

BioElectronics Executes Distribution Agreement with KT Health, LLC for North American Retail Market

GlobeNewswire December 15, 2020

BioElectronics Earns CE Mark for the ActiPatch and RecoveryRx -- Drug-Free Pain Therapy Devices

GlobeNewswire November 12, 2020

BioElectronics' ActiPatch® Therapy To Be Marketed By DonJoy® Advantage

PR Newswire November 6, 2020

BioElectronics Chairman Outlines New Direction for Company

GlobeNewswire August 10, 2020

Richard Staelin, Ph.D. Rejoins the Board of BioElectronics Corporation

GlobeNewswire June 15, 2020

BioElectronics Announces U.S. FDA Market Clearance for Over-The-Counter Treatment of Musculoskeletal Pain

GlobeNewswire February 3, 2020